Urokinase

CAS 9039-53-6

Also known as: Tissuecultureurokinase

Urokinase (trade name Abbokinase), also called urokinase-type plasminogen activator (uPA), is a serine protease (EC3.4.21.73). It was discovered in 1947 by McFarlane. Urokinase was originally isolated from human urine, but is present in several physiological locations, such as blood stream and the extracellular matrix. The primary physiological substrate is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin. Activation of plasmin triggers a proteolysis cascade that, depending on the physiological environment, participates in thrombolysis orextracellular matrix degradation. This links urokinase to vascular diseases and cancer.

Request a Quote
Category: Pharmaceutical Chemicals APISubcategory: Circulatory System Drugs APIProduct ID: urokinase-9039-53-6
Payment & Shipping Terms Supply Capacity
Payment Terms: T/T, WU Production Capacity: 500Ton/year
Min. Order: 1 Gram Packing: according to the customer's requirements
Means of Transport: Ocean, Air, Land Delivery Date: 7 days

Urokinase ( CAS: 9039-53-6)

Item Index
Molecular Formula C21H25BrN2O3
Specification CP/USP/EP
Appearance White powder
Storage Condition 2-8°C

Urokinase (trade name Abbokinase), also called urokinase-type plasminogen activator (uPA), is a serine protease (EC3.4.21.73). It was discovered in 1947 by McFarlane. Urokinase was originally isolated from human urine, but is present in several physiological locations, such as blood stream and the extracellular matrix. The primary physiological substrate is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin. Activation of plasmin triggers a proteolysis cascade that, depending on the physiological environment, participates in thrombolysis orextracellular matrix degradation. This links urokinase to vascular diseases and cancer.

Molecular characteristics

Urokinase is a 411-residue protein, consisting of three domains: the serine protease domain, the kringle domain, and thegrowth factor domain. Urokinase is synthesized as a zymogen form (prourokinase or single-chain urokinase), and is activated by proteolytic cleavage between Lys158 and Ile159. The two resulting chains are kept together by a disulfidebond.

Urokinase and cancer

Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. It is believed that the tissue degradation following plasminogen activation facilitates tissue invasion and, thus, contributes to metastasis. This makes urokinase an attractive drug target, and, so, inhibitors have been sought to be used as anticancer agents. However, incompatibilities between the human and murinesystems hamper clinical evaluation of these agents. Through its interaction with the urokinase receptor, urokinase affects several other aspects of cancer biology such as cells adhesion, migration, and cellular mitotic pathways.

As of December 7, 2012 Mesupron®, a small molecule serine protease inhibitor developed by the WILEX pharmaceutical company, has completed phase II trials. Mesupron appears to be safe when combined with chemotherapeutic drug Capecitabine for the progression-free survival in human breast cancer.

CAS Number 9039-53-6
Model CAS:9039-53-6
Place of Origin Shandong,China (Mainland)
Brand MOSINTER
Storage condiion 2-8°C
Form powder
Color white
Request a quote

Send an inquiry for Urokinase

By sending this inquiry, you acknowledge our Privacy Policy. We use these details only to answer your request.

We usually respond within one business day.

×
MOSINTER chemical operations

Request a Quote

By sending this inquiry, you acknowledge our Privacy Policy. We use these details only to answer your request.

We usually respond within one business day.

MOSINTER GROUP